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Advantages of drug-eluting stents (DES) for coronary artery dis-
ases are widely accepted because of their signiﬁcant reduction of
estenosis and of target lesion revascularization compared to bare-
etal stents (BMS) [1]. However, in-stent thrombosis (IST), a rare
ut unpredictable and tragic event, has been reported after DES
mplantation. IST often leads to a catastrophic outcome and overall
rognosis from IST is poor: 10–30% of patients with IST will die [2].
o difference between DES and BMS  is seen for the incidence of
arly IST (<30 days) or late IST (30 days to 1 year); however, sig-
iﬁcantly higher rates of very late IST (>1 year) are seen with DES
3]. Data from several registries have indicated that the risk of very
ate IST persists at an annual rate of 0.36–0.6% per year to at least 5
ears after DES implantation [4,5]. The current on-label indications
or DES are limited to simple lesions and off-label indications repre-
ent a higher risk population with complex morphology. Thus, the
isk of IST is higher for the patients treated with DES for off-label
ndications compared with on-label indications.
The pathogenesis of IST is probably multi-factorial and numer-
us factors have been implicated in increasing the risk of an
ST event [6]. Precipitants of IST include patient factors, such
s acute coronary syndrome lesion, diabetes mellitus, renal dys-
unction, low left ventricular output, and early cessation of dual
nti-platelet therapy (DAPT). Lesion characteristics, such as severe
alciﬁed lesion, bifurcation lesion, and chronic total occlusion may
ontribute the pathogenesis of IST. Procedural factors, such as
ncomplete stent apposition, stent deployment over the lipid rich
ecrotic core, multiple stent implantation, long target lesion, and
tent undersizing have been also shown to be important in the
evelopment of IST.
Histological  observation indicates that foreign body reaction
gainst DES is clearly different from the corresponding lesions
ccurring after BMS  implantation. In our experience of autopsy
ases, ﬁrst-generation DES suppresses the early immune response
f the treated artery compared to BMS  [7]. Furthermore, delayed
rterial healing processes, such as incomplete endothelial cell
overing, lack of intimal thickening, and persistent ﬁbrin depo-
ition have been identiﬁed after DES implantation (Fig. 1). These
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preclinical experiments at 28 days after treatment with DES, the
delayed arterial healing compared to BMS  was overlooked. Rapid
endothelial covering after DES deployment in animal models con-
trasts with the delayed healing processes after DES implantation in
human coronary arteries. Furthermore, the inﬂuence of advanced
atherosclerotic lesion on the healing processes after DES implan-
tation should be taken into account. Plaque components, such
as lipids, inﬂammatory cells, necrotic debris, extracellular matrix,
and thrombus, may  inﬂuence drug release, retention, absorption,
and distribution. In fact, DES implantation after acute myocardial
infarction results in apparently delayed vascular healing, compared
to DES treatment in patients with stable angina.
One of our autopsy cases has shown the complete stent strut
coverage with re-endothelialization after 6 months of sirolimus-
eluting stent (SES) implantation (Fig. 2). In contrast, a previously
reported case at 15 months after SES deployment has shown min-
imal coverage of the struts by ﬁbrin with rare endothelial cells. In
addition, incomplete strut coverage is demonstrated by coronary
angioscopy persisting as late as 24 months after SES implantation
[8]. This discrepancy indicates that the response to DES deployment
in human coronary artery is heterogeneous. There is no doubt that
DES resulted in delayed arterial healing compared to BMS, whereas
it appears difﬁcult to evaluate the chronologic evolution of changes
after DES implantation. The local responses to DES deployment may
be affected by a variety of factors, such as stent length, apposition of
struts, anatomical location, histological features of the underneath
plaque, blood ﬂow speed and turbulence, and immune reactivity of
each individual. Therefore, the optimal duration of DAPT after DES
implantation remains controversial. Whereas we need to keep it in
mind that discontinuation of DAPT at less than 1 year after stent
implantation is one of the most signiﬁcant independent predictors
of IST along with poor compliance, surgery, bleeding complications,
and allergy to clopidogrel [9].
An analysis of the lesions in 32 autopsy cases shows a mean
55.8 ± 26.5% of struts with re-endothelialization after a mean DES
implantation of 223 ± 253 days; in contrast to DES, 36 BMS  lesions
showed 89.9 ± 20.9% strut re-endothelialization at 299 ± 360 days
[6]. Studies using optical coherency tomography (OCT) have shown
that the rate of uncovered stent struts is lower in the second gener-
ation of zotarolimus-eluting stent, when compared with SES [10].
A comparative study of stents with biodegradable polymer versus
stents with durable polymer using OCT images indicates signiﬁ-
cantly higher rate of stent coverage with biodegradable polymer
stent [11]. This result suggests that not only eluting drug itself, but
also polymer may  participate in the endothelial cell coverage over
stent struts.
vier Ltd. All rights reserved.
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Fig. 1. Local reactions against sirolimus-eluting stent at 2 months after implanta-
tion.  Stent struts apparently exposed to the blood ﬂow and ﬁbrin deposits on the
luminal surface between the stent struts. Few inﬂammatory cells except several for-
eign body giant cells inﬁltrate near stent struts. No endothelial cell coverage over
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wtent struts is apparent (hematoxylin–eosin, 200×).
The ability to induce hypersensitivity reactions through the
resence of a polymer deserves additional consideration. Perma-
ent polymer facilitates drug release and remains after complete
rug elution. Histopathological studies have shown that the poly-
ers induce localized vascular inﬂammation, hypereosinophilia,
hrombogenic reactions, and apoptosis of smooth muscle cells
12]. The Cypher SES (Cordis, Bridgewater, NJ, USA) is coated in a
urable polymer, which has been shown to induce hypersensitiv-
ty in human. The Taxus paclitaxel-eluting stent (Boston Scientiﬁc,
atick, MA,  USA) also has a durable polymer that has been shown
o be associated with positive remodeling. These device concerns
eed to be improved for the development of next generation DES.
he possibility of IST according to a permanent polymer led to the
evelopment of second-generation DESs with biocompatible and
iodegradable polymers. These new polymers have been shown to
ave a greater degree of re-endothelialization compared to ﬁrst-
eneration DESs.
ig. 2. Complete stent strut coverage with re-endothelialization after 6 months
f  sirolimus-eluting stent implantation. Minimal but sufﬁcient intimal thickening
ompletely covers the stent struts. A few lymphocytes inﬁltrate around stent struts
ithout destructive reaction to the vessel wall (hematoxylin–eosin, 100×).
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Sonoda et al. [13] have demonstrated intravascular ultrasound
(IVUS) images and histopathology of a very late IST case. They
have observed late-acquired stent malapposition with positive
remodeling at the level of SES implantation by IVUS imaging. Histol-
ogy indicates ﬁbrin thrombi formation at the level of malapposed
stent struts. Inﬂammatory cell inﬁltration is prominent around
stent struts and arterial wall has shown the destructive reaction.
They have shown that multinucleated giant cells, B-lymphocytes,
plasma cells, and eosinophils were identiﬁed around the stent
struts. These pathological alterations are similar to the previously
reported hypersensitivity induced IST cases. In spite of the mas-
sive inﬂammatory reaction against DES struts, the lack of clinical
evidence of hypersensitivity vasculitis, such as hypereosinophilia,
high serum IgE value, and elevated high sensitive C-reactive protein
level is noteworthy. Furthermore, we  need to learn from this patient
that marked positive remodeling and stent malapposition by vas-
cular imaging may  represent a massive inﬂammatory reaction with
vessel wall destruction: lesion with extremely high thrombogenic
potential.
Observation of alterations occurring after DES implantation by
imaging techniques, such as IVUS, OCT, and coronary angioscopy,
may furnish important information on the conditions of DES-
treated vessels. In order to achieve more accurate diagnosis in vivo,
comparative data between vascular imaging and histopathology
ﬁndings is required to improve interpretation of imaging. Further-
more, our understanding of IST pathogenesis should be facilitated
by the knowledge of pathological alterations present in coronary
arteries treated with DES devices. From this viewpoint, accumula-
tion of information concerning histopathology at the level of the
DES implanted artery is imperative.
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